ATE381345T1 - Alpha-emittierende konstrukte sowie deren verwendung - Google Patents

Alpha-emittierende konstrukte sowie deren verwendung

Info

Publication number
ATE381345T1
ATE381345T1 AT99940789T AT99940789T ATE381345T1 AT E381345 T1 ATE381345 T1 AT E381345T1 AT 99940789 T AT99940789 T AT 99940789T AT 99940789 T AT99940789 T AT 99940789T AT E381345 T1 ATE381345 T1 AT E381345T1
Authority
AT
Austria
Prior art keywords
cells
alpha
constructs
emitting
emitting constructs
Prior art date
Application number
AT99940789T
Other languages
English (en)
Inventor
David Scheinberg
Dangshe Ma
Michael Mcdevitt
George Sgouros
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE381345T1 publication Critical patent/ATE381345T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Revetment (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99940789T 1998-05-26 1999-05-26 Alpha-emittierende konstrukte sowie deren verwendung ATE381345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8677298P 1998-05-26 1998-05-26

Publications (1)

Publication Number Publication Date
ATE381345T1 true ATE381345T1 (de) 2008-01-15

Family

ID=22200805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940789T ATE381345T1 (de) 1998-05-26 1999-05-26 Alpha-emittierende konstrukte sowie deren verwendung

Country Status (7)

Country Link
EP (1) EP1091757B1 (de)
JP (1) JP5064608B2 (de)
AT (1) ATE381345T1 (de)
CA (1) CA2333125C (de)
DE (1) DE69937797D1 (de)
ES (1) ES2299256T3 (de)
WO (1) WO1999061097A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
EP2727606A3 (de) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
JP2025500843A (ja) * 2021-12-14 2025-01-15 ボストン サイエンティフィック サイムド，インコーポレイテッド 放射性せん断減粘生体材料組成物および使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
JPH05503632A (ja) * 1989-12-14 1993-06-17 スローン　―　ケターリング・インスティチュート・フォー・キャンサー・リサーチ モノクローナル抗体ｍ１９５の超可変領域の治療的使用およびその構築
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
EP1091757A4 (de) 2002-08-07
CA2333125A1 (en) 1999-12-02
WO1999061097A9 (en) 2000-06-02
JP2002516297A (ja) 2002-06-04
WO1999061097A2 (en) 1999-12-02
DE69937797D1 (de) 2008-01-31
JP5064608B2 (ja) 2012-10-31
ES2299256T3 (es) 2008-05-16
EP1091757A2 (de) 2001-04-18
WO1999061097A3 (en) 2000-02-03
CA2333125C (en) 2009-12-15
EP1091757B1 (de) 2007-12-19

Similar Documents

Publication Publication Date Title
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
BG63122B1 (bg) Съединения и методи за лечение на рак
FI951295A0 (fi) Ihon läpi tapahtuva veressä olevien valoherkkien aineiden in vivo-aktivointi
EP0746625A4 (de) Erzielbare vektorenpartikel
GB8919251D0 (en) Compounds
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
ES2054038T3 (es) Esteres y tioesteres aromaticos, su procedimiento de preparacion y su utilizacion en medicina humana o veterinaria y en cosmetica.
AR007493A1 (es) Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica
ATE33556T1 (de) Adenosinderivate enthaltende pharmazeutische zusammensetzung fuer behandlung von tumoren.
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
ATE260692T1 (de) Drahtförmige strahlungsquelle zur endovaskulären bestrahlung
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DE69937797D1 (de) Alpha-emittierende konstrukte sowie deren verwendung
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
ES2036526T3 (es) Composiciones de interferon.
AU6751294A (en) Protection from shock subsequent to injury by double-standard RNAs
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
PT871467E (pt) Formulacao para a libertacao de peptido
ATE407702T1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb
DE3883044D1 (de) Wirkstoff zur tumorbekaempfung.
Strander The action of interferons on virus-associated human neoplasms
MX9602407A (es) Composiciones farmaceuticas.
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties